The inaugural edition of the Emerging Technologies and Trends in Identity Verification (IDV), KYC, and KYB Report 2024 offers a comprehensive overview of the key technology trends and best practices in digital onboarding for consumers and businesses in 2024.

The 1st edition of the Fintech for Marketplaces and Platforms Report covers essential ecommerce trends and future perspectives.

The first edition of the Unlocking the Potential of A2A Payments Report 2024 provides the latest insights into the A2A space.

Unlock unparalleled insights into the transformative world of Embedded Finance and Banking-as-a-Service (BaaS) with The Paypers' latest report. Dive deep into essential business models, key players, and the latest trends reshaping industries with our comprehensive guide, curated by industry experts and leading companies.

The 6th edition of the Fraud Prevention in Ecommerce Report provides a thorough overview of the global fraud ecosystem.

 ‘The Road Ahead: Towards Seamless Payments Interoperability’, an eBook from Thunes, Visa, and The Paypers, explores how payments interoperability is reshaping the future of cross-border transactions.

The Next-Gen Technologies to Detect Fraud and Financial Crime Report 2024 highlights how banks, fintechs, and PSPs leverage AI and emerging tech to detect and combat advanced fraud.

BuzzAR has launched BuzzPay,...

Thunes, a global cross-border payments platform, has announced a...

Source: Streetwise Reports 11/06/2024

Terawulf Inc. (WULF:NASDAQ) has reported its October 2024 production and operations. The report included significant advancements in self-mining with an operational capacity reaching 8.1 exahash per second (EH/s). This marks a 62% increase from the prior year. The company mined a total of 150 bitcoins during the month, averaging approximately 4.8 bitcoins per day, at a power cost of US$36,789 per bitcoin mined or about US$0.048 per kWh (kilowatt-hour). To improve efficiency, TeraWulf continued its miner refresh program at its Lake Mariner facility, replacing older models with upgraded S19 XP miners following its sale of interest in the Nautilus Cryptomine facility, which enabled additional hardware acquisitions.

Focusing on high-performance computing (HPC) infrastructure, TeraWulf's aim is to establish 72.5 MW HPC hosting capacity at Lake Mariner by Q2 2025. October's operational hash rate averaged 6.8 EH/s, with adjustments made for demand response events and performance optimization measures to enhance profitability. Construction on the company's 20 MW HPC hosting facility, CB-1, remains on schedule for Q1 2025, and a larger 50 MW HPC facility, CB-2, is expected by Q2 2025. The recent sale of TeraWulf's equity interest in Nautilus and new financing through convertible notes are anticipated to support these growth initiatives.

Sean Farrell, Senior Vice President of Operations at TeraWulf, explained in the press release, "October marked another productive month, with TeraWulf mining 150 bitcoin and sustaining an average daily production of around 5 bitcoin . . . In line with our previously outlined plans, we are accelerating the transition to more efficient mining hardware by replacing older miners at Lake Mariner with S19 XP models. We are also working closely with Bitmain's warranty department on a recovery plan to repair and replace 1.5 EH of mining equipment with a target completion by the end of the year. Furthermore, we have established a dedicated Business Development and Performance Optimization team focused on integrating advanced IT and software solutions to improve our operational hash rate and overall efficiency. Building 5, which has been designed to handle higher heat exhaust of the latest generation miners, remains on track to be operational in Q1 2025."

Why Crypto Mining?

The cryptocurrency mining sector has seen recent momentum, bolstered by the U.S. election results and the evolving landscape for Bitcoin. As Benzinga reported on November 6, bitcoin mining stocks experienced notable gains following the U.S. presidential election, which led to Bitcoin reaching record highs. The outcome was anticipated to benefit U.S.-focused mining companies as pro-crypto policies, including a preference for domestic bitcoin production, gained prominence. Benzinga noted that Trump had previously expressed support for more bitcoin mining within the U.S., a stance that influenced broader market optimism in the days following his election.

On November 4, Yahoo! Finance highlighted the growing trend among Bitcoin miners to integrate artificial intelligence (AI) to power a "new industrial revolution." As described by Rob Nelson, who emphasized the impact of cryptocurrency mining as a vehicle for both economic and technological change. This trend has driven miners to secure deals within the AI sector, given the synergies in computational power required for both cryptocurrency and AI initiatives. Nelson projected that this cross-industry expansion could have far-reaching effects, creating value for both miners and AI-focused enterprises.

Additionally, a November 6 report from Time explored the significance of the recent Presidential election outcome for the crypto industry's future regulatory environment. According to Time, Trump's support for the industry included ambitions to boost the country's bitcoin mining footprint, which aligned with crypto PACs' efforts to secure pro-crypto candidates. The article reported that these advocacy groups saw the election as an opportunity to reshape crypto regulation and encourage growth in U.S.-based bitcoin mining.

TeraWulf's Catalysts

TeraWulf's recent initiatives set a foundation for further growth and operational efficiency. According to the company's investor presentation, the sale of its 25% equity interest in the Nautilus facility enhances liquidity. This enables TeraWulf to reinvest in its flagship Lake Mariner site for both HPC and AI expansion.

The transaction also reduces exposure to the expiring Nautilus 2¢ power contract by 2027, positioning the company to benefit from projected power price increases at Lake Mariner. This strategic realignment is anticipated to improve fleet efficiency, with an upgraded mining fleet targeting 13 EH/s by Q1 2025, supported by the deployment of next-gen S21 Pro miners.

What Experts Are Saying...

On November 5, 2024, Roth MKM analyst Darren Aftahi assigned TeraWulf a "Buy" rating and set a price target of US$7.50. Roth highlighted optimism around the company's expansion and potential in high-performance computing (HPC) and bitcoin mining. Roth noted that TeraWulf's planned 72.5 MW of HPC capacity by Q2 2025 could generate annualized revenue of approximately US$90 million, with over US$60 million in profit. [OWNERSHIP_CHART-11184]

The report highlighted the completion of TeraWulf's initial 2.5 MW HPC project and its upcoming 20 MW facility, which remains on track for Q1 2025. Roth analysts pointed to the operational progress at TeraWulf's Lake Mariner facility, emphasizing the company's improvements in mining efficiency with new S19 XP models, which brought its machine efficiency to 22 J/TH.

Ownership and Share Structure

According to Refinitiv, management and insiders hold 6.67% of TeraWulf. Of them, Co-founder, COO, and CTO Nazar M. Khan holds the most, with 4.43%.

Strategic investors hold 21.37%. Of them, Riesling Power LLC holds the most at 5.23%, Baryshore Capital LLC holds 4.77%, Revolve Capital LLC has 4.67%, Opportunity Four of Parabolic Ventures owns 2.46%, and Lake Harriet Holdings LLC has 1.90%.

Institutions have 45.11%. The largest holders there are The Vanguard Group at 6.12%, BlackRock Instituional Trust with 4.22%, Two Sigma Investments LP at 2.28%, Beryl Capital Management LLC holds 1.74%, and Geode Capital Management LLC has 1.66%. The rest is retail.

TeraWulf has a market cap of US$2,375.93 million and 275.29 million free float shares. Their 52-week range is US$ 0.8911 - 7.28.
Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1) James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.

2) This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

( Companies Mentioned: WULF:NASDAQ, )

File: Stephen Yan dresses as Deadpool at Comic-Con on July 19, 2013 in San Diego.; Credit: Sandy Huffaker/Getty Images

Hey, you! Yeah, you reading this! They're finally making a Deadpool movie!

If you like fourth-wall breaking, second-person addresses like the above, you may be in the target audience for the long-in-development "Deadpool," which Twentieth Century Fox announced Thursday that it was finally moving ahead with, according to the Hollywood Reporter. The studio announced a Feb. 12, 2016 release date for the film with Tim Miller set to direct the character who's served as both friend and foe to the X-Men.

The so-called "Merc with a Mouth" is a mercenary character created in the early '90s by artist Rob Liefeld, with Liefeld being an outspoken champion for the character. The character was part of the same Weapon X program that created Wolverine, with a similar healing factor power, but with a horribly scarred face he covers with a mask. He's also been played as crazy, which manifests itself as the character often knowing he's in a comic book and talking directly to the reader.

Ryan Reynolds has long been tied to the project, including playing a version of the character in the much-hated "X-Men Origins: Wolverine," but no deal has been made yet, according to the Reporter.

This follows footage leaking over the summer of a "Deadpool" test with Reynolds voicing the character in a CGI clip. Reynolds said in an interview in the Niagara Falls Review earlier this month that that it's unfortunate the footage leaked, "but who cares," because the positive response to the clip had helped push the film forward after being stuck in development hell.

"The movie has been in a state of limbo for a while. There was such an overpowering reaction to the footage, you sort of feel like, 'Oh, so we weren't crazy for our reasons for loving this character, for loving this role.' It's interesting to see the power of the Internet. It's awe-inspiring, actually," Reynolds told the Review. "And it's neat that Twitter and Facebook and Instagram can move mountains when used in the right way."

Watch the "Deadpool" test footage below (Warning: Contains some adult language):

Deadpool test footage

There'd also been debate about whether a movie would stay true to the character's outrageous attitude mixed with violence and go for an R rating, or whether it would go for a wider audience by staying at PG-13. Deadpool creator Liefeld has argued that the film would work just fine without restricting its audience with an R.

Liefeld tweet 1

Liefeld tweet 2

Liefeld told the Daily Superhero in a previous interview that the footage for the test was filmed three years ago, using motion capture over footage of Reynolds. He also talked up Miller as a director, noting that he directed the pre-credits scene for "Thor: The Dark World."

"Fox had released a relatively small budget for Tim to present his vision of the script written by Rhett Reese and Paul Wernick," Liefeld said. "The digital costume over Ryan Reynold's motion capture (Mo-Cap) performance was an approach they wanted to explore and they had a relatively small window to create this short so they opted to 'test' the look of a digital Deadpool costume over Ryan. I'm quite pleased at how it turned out, especially considering Baraka-Deadpool from Wolverine Origins."

Liefeld was referring to the transformation of Deadpool in "X-Men Origins: Wolverine" to a mouthless, pointy-limbed character in the film, which many fans argued took away what they loved most about Deadpool: His sense of humor. Liefeld also said he'd seen even more impressive sequences than the one that made its way online.

It's unclear whether this will tie in with the other X-Men films, but with the studio's recent attempt to tie together the "First Class" franchise with the older X-Men films in "Days of Future Past" and the character's long history of involvement with the X-Men and other related teams, it seems like a likely move.

Source: Streetwise Reports 10/18/2024

Aero Energy Ltd. (AERO:TSXV; AAUGF:OTC; UU3:FRA) has announced significant advancements at its Murmac and Sun Dog uranium projects in Northern Saskatchewan, with the first drill program revealing high-grade uranium potential. Situated near Uranium City on the Athabasca Basin's northern margin, the projects aim to capitalize on basement-hosted uranium deposits similar to high-grade discoveries in the region.

The initial drill campaign completed 16 holes, targeting 12 key areas, with 12 holes yielding anomalous radioactivity. A major highlight is the new high-grade uranium discovery in drill hole M24-017, which intersected 8.4 meters of mineralization at 0.3% U3O8, including assays peaking at 13.8% U3O8 at just 64 meters below surface. The results confirm Aero's exploration model, which focuses on basement-hosted deposits within graphitic structures, a common feature in Athabasca Basin uranium deposits like Arrow and Triple R.

"From the launch of the company in January, we took a very diligent yet aggressive approach to discovery," stated Galen McNamara, CEO of Aero Energy. "The combination of historical data and the results from the first drill program serve as evidence that basement-hosted mineralization akin to the large deposits beneath and adjacent to the Athabasca Basin is present in the area."

The Murmac project spans 25,607 acres and holds a production legacy of approximately 70 million pounds of U3O8. Similarly, the 48,443-acre Sun Dog property hosts the historic Gunnar uranium mine, which once held the title of the world's largest uranium producer. Past exploration focused on fault-hosted mineralization, missing the basement-hosted uranium potential that Aero's recent findings have validated.

Recent exploration efforts included a VTEM Plus survey, flown over 3,350 kilometers, identifying graphite-rich rocks that support Aero's exploration thesis. Additionally, two new occurrences of strong radioactivity were identified at surface-level scout locations: Target A15 showed 60,793 counts per second, and Target P4 displayed 13,533 counts per second. Summer 2024 drilling included 1,550 meters at Murmac and 1,600 meters at Sun Dog, highlighting shallow, high-grade potential in both areas.

In parallel, Aero Energy has announced a CA$2.5 million non-brokered private placement to support further exploration. The proceeds from flow-through units will fund work programs across Murmac, Sun Dog, and the Strike property, with the remaining funds allocated to general working capital.

Why Uranium?

The uranium sector has recently experienced strong growth, largely driven by increasing global demand and efforts to diversify from Russian supply chains. On September 30, The New York Times discussed the resurgence in Western uranium production, highlighting that "uranium mines are ramping up across the West, spurred by rising demand for electricity and federal efforts to cut Russia out of the supply chain." Aero Energy's recent discoveries and forthcoming winter drilling plans at Murmac and Sun Dog reflect this trend, with CEO Galen McNamara remarking, "The combination of historical data and the results from the first drill program serve as evidence that basement-hosted mineralization . . . is present in the area," suggesting strong potential for the Canadian uranium market to contribute to non-Russian nuclear fuel supplies.

Jeff Clark of The Gold Advisor highlighted his continued confidence in the company by stating, "I remain overweight the stock."

On October 9, Reuters reported that demand from U.S. buyers has been on the rise, as "a strong rise in demand from its U.S. customers" pushed Orano's recent plans to expand uranium enrichment in the United States and France. This shift underscores Aero Energy's recent investments in Northern Saskatchewan, where the company has identified high-grade uranium mineralization in both the Murmac and Sun Dog projects, aiming to meet future supply demands with a focus on basement-hosted deposits.

As Forbes reported on October 11, the uranium market experienced renewed momentum after Russian President Vladimir Putin hinted at the possibility of a ban on uranium exports to Western nations. This suggestion "jolted the uranium market," which had been declining after peaking earlier in the year. The price of uranium rebounded to US$83.50 per pound, reflecting rising concerns about potential supply disruptions. Citi analysts noted that “Russia supplies close to 12% of U3O8, 25% of UF6, and 35% of EUP to international markets,” underscoring the challenges that Western nations, particularly the U.S. and Europe, could face in replacing these critical materials. This market dynamic positions uranium companies operating outside of Russia, like those in the Athabasca Basin, to benefit from supply gaps and heightened demand.

MSN reported on October 13 that the UK's nuclear power capacity is set to decrease dramatically in the coming years, with the planned closure of four out of five remaining nuclear plants by 2028. This reduction in capacity is expected to increase pressure on global uranium supplies as demand for nuclear energy continues to rise amid efforts to meet climate goals. The ongoing shift toward low-carbon energy sources, coupled with the planned closures, could create further supply constraints and drive demand for uranium from alternative sources.

Aero's Catalysts

According to the company's October 2024 investor presentation, the ongoing development at Murmac and Sun Dog highlights Aero Energy's strategy to enhance shareholder value by targeting high-grade uranium deposits in underexplored regions. Aero has leveraged recent technology investments, including VTEM Plus aerial surveys, which identified graphite-rich formations favorable for uranium. The exploration efforts build on the CA$7.6 million previously invested by project partners Fortune Bay and Standard Uranium, which has contributed to refining the drill targets. As Aero works with its partners to maximize the impact of this winter's drilling program, the company's strategic location on the north rim of the Athabasca Basin positions it well to expand these discoveries and attract continued investor interest.

The recently announced CA$2.5 million private placement will further strengthen Aero's financial capacity to carry out its targeted drill campaigns and exploration work.

Analyzing Aero

Jeff Clark of The Gold Advisor, in his October 17 update, noted that Aero Energy has "identified more than 70 kilometers of strike to test for high-grade basement-hosted uranium," emphasizing the company's significant exploration potential in a region known for some of the world's richest uranium deposits.

Clark further commented on Aero Energy's recent results, underscoring the importance of drill hole M24-017, which intersected 8.4 meters of uranium mineralization, grading 0.3% U3O8, with assays reaching as high as 13.8% U3O8. He stated, "While not a discovery hole, per se, this hole underscores the company's thesis that these two projects are prospective for the same type of uranium mineralization as Arrow and Triple R." This observation reinforces Aero Energy's exploration model, which targets basement-hosted uranium deposits similar to those found at other significant Athabasca Basin discoveries. [OWNERSHIP_CHART-11173]

Additionally, Clark expressed optimism regarding Aero Energy's current valuation and future prospects, recommending it as a strong buy at current levels. He highlighted his continued confidence in the company by stating, "I remain overweight the stock," suggesting that Aero Energy presents a compelling opportunity for speculative investors in the uranium exploration space.

The recently announced CA$2.5 million private placement was also acknowledged by Clark as a necessary step to fund further exploration activities. While he expressed some caution about potential dilution, he affirmed his overall support for the financing, noting that "its projects are very much worthy of follow-up."

Ownership and Share Structure

According to Refinitiv, management and insiders own 3.11% of Aero Energy. Of those, CEO Galen McNamara has the most at 2.97%. Institutions owns 4.79% with MMCAP Asset Management holding 3.89%. The rest is retail.

Aero has 92.3 million free float shares and a market cap of CA$4.5 million. The 52 week range is CA$0.040–$0.26.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1) James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.

2) This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

( Companies Mentioned: AERO:TSXV;AAUGF:OTC;UU3:FRA, )

Source: Streetwise Reports 11/05/2024

Revolve Renewable Power Corp. (TSXV:REVV; OTCQB:REVVF) released its strongest financial results since going public in 2022, those for fiscal year 2024 (FY24) ended June 30, 2024, the company announced in a news release.

"FY24 marked significant progress for the company as it continues its transition to an owner and operator of renewable energy projects, incorporating a focus on building long-term recurring revenues and cash flow for the business," the release noted.

This company, headquartered in British Columbia, develops utility-scale solar, wind, hydro, and battery storage projects in North America. The Revolve Renewable Business Solutions division installs and operates sub-20-megawatt, behind-the-meter distributed generation assets.

FY24 revenue of US$6.7 million (US$6.7M) exceeded guidance by 35% and surpassed FY23 revenue by 509%. Significant contributors to total revenue for this latest fiscal year were deferred revenues and milestone payments of US$4.25M from the sale of the Bouse and Parker projects to ENGIE. Completion of the WindRiver Power Corp. acquisition in February added $671,738 of total revenue. In the future, WindRiver business is projected to generate recurring revenue of US$1.8M on a 12-month basis.

Adjusted EBITDA in FY24 also was up year over year (YOY), at US$2.7M versus US$1.5M of guidance and (US$2.1M) in FY23.

The gross margin in FY24 was strong at 96%. This was due to increased recurring revenues from the distributed generation portfolio, low operating costs of the rooftop solar projects therein, the addition of operating utility-scale projects in Canada, and sale proceeds from utility-scale projects in the U.S.

FY24 resulted in a net income of US$2.6M, whereas FY23 saw a net loss of US$2.3M.

As for the balance sheet, at FY24's end, Revolve had US$3.2M in cash. Total liabilities were US$10M, up from US$2.6M in FY23 due to nonrecourse debt taken on via the WindRiver acquisition plus additional loans granted by RE Royalties Ltd., a Canadian royalty finance company, throughout FY24.

Operational Progress Made

Operationally, in FY24, according to the release, Revolve generated 8,048,729 kilowatt-hours (8,048,729 kWh) of renewable energy, up 397% from 1,618,456 kWH the year before. The main drivers were continuing output from the company's operational distributed generation portfolio and power produced at the Box Springs wind farm.

During the 15 months between July 1, 2023, and Oct. 31, 2024, Revolve added of 76.1 megawatts (76.1 MW) net of development hydro projects in Canada through the WindRiver acquisition and 480 MW of new greenfield development projects in Canada and the U.S. These took the total of Revolve's utility-scale projects under development to 3,015 MW.

The company made significant progress on its 20 megawatt (20 MW)/80 MWh Vernal BESS battery storage project and 49.5 MW Primus wind projects, now in the late stage of development and expected to reach ready-to-build status at the end of 2025 (2025E).

Revolve is still building its two distributed generation assets in Mexico, totaling 3.45 MW. Permitting work continues on the 3 MW CHP project continues, and the final commissioning of the 450-KW-peak rooftop solar project is taking place.

The distributed generation project pipeline remains at about 150 MW, and efforts are ongoing to sign additional power purchase agreements for new projects from it.

Also, Revolve recently announced its acquisition of a 30-MW-peak solar development project in Alberta, Canada, and expects a 20-MW-peak first phase will be ready for construction by 2025E.

Independent Power Producer

Revolve is a revenue-generating, renewable-focused independent power producer formed in 2012 to capitalize on the growing global demand for renewable power, according to its October 2024 Corporate Presentation.

The company began as solely a developer of utility-scale projects, a line of business that provides investors access to higher returns. Currently, the company has two projects under construction, the ones in Mexico and 3,000-plus MW worth of projects in development in Canada, the U.S., and Mexico. To date, Revolve has developed and sold more than 1,550 MW of utility-scale projects and is now targeting 5,000 MW under development.

Today, Revolve is also an owner-operator of renewable energy distribution generation projects that provide recurring revenue and cash flow via long-term power purchase agreements. Currently, the portfolio contains 150-plus MW of generation projects in Canada and Mexico. The company will continue expanding this line of business through organic growth and mergers and acquisitions (M&A) activity.

Revolve's management team has a successful track record in taking renewable energy projects from greenfield to ready-to-build status and in selling them to large operators. Collectively, it has generated about US$23M in revenue historically from the sale of 1,550 MW of development assets and has raised US$10.3M in equity capital.

Significant Sector Growth Forecasted

The transition to net zero emissions continues driving the renewable energy industry after nearly 200 countries at the COP28 UN Climate Change Conference in December 2023 pledged to triple global capacity by the end of this decade. In a report last month, the International Energy Agency (IEA) forecasted global renewable capacity reaching almost 11,000 gigawatts (GW) by then, reflecting 2.7 times growth, falling short of the goal.

Solar Photovoltaic (PV) Power: Of the growth predicted for renewable energy during this period, solar photovoltaic power will make up 80% of it, according to the IEA, due to its increasing economic attractiveness in most countries.

"At the end of this decade, solar PV is set to become the largest renewable source, surpassing both wind and hydropower," the agency wrote. Hydropower currently is the top source worldwide.

Wind Power: Wind power will account for 15% of all forecasted renewable capacity growth, noted the IEA. This sector has suffered recently from macroeconomic factors and supply chain difficulties, but it is expected to recover. Global wind capacity is projected to expand between 2024 and 2029 at double the rate it grew between 2017 and 2023.

"Policy changes concerning auction design, permitting, and grid connection in Europe, the United States, India, and other emerging and developing economies are expected to enhance project bankability and help the wind sector recover from recent financial difficulties," the article noted.

Hydropower: As for hydropower, capacity is continuing to grow consistently, noted the IEA, due primarily to efforts by China, India, Africa and the Association of Southeast Asian Nations region.

In North America, the U.S. is expected to be the biggest market for hydropower, according to Mordor Intelligence. Between 2024 and 2029, the market is forecasted to expand at a compound annual growth rate of 1%, spurred by demand for renewable energy and investments in hydropower plants.

"The technological advancements in efficiency and decrease in the production cost of hydropower projects are expected to create ample opportunity for market players," the article noted.

The Catalysts: Results of Business as Usual

As Revolve continues effecting its growth strategies, numerous potential stock-boosting events should occur, according to its corporate presentation.

Catalysts resulting from ongoing efforts include further M&A transactions, signing additional power purchase agreements, and bringing new distributed generation projects online. wo increasing revenue and cash flow growth.

Specifically, the company reaching its goals of advancing 70 MW of the BESS and Wind projects to ready-to-build status as well as 30 MW of solar in Canada, in 2025. These have the potential to generate material revenue and add value.

Another catalyst is Revolve achieving ready-to-build status for its two wind projects in Mexico, the 103 MW El 24 and the 400 MW Presa Nueva. The company's ultimate goal with these assets is to partner on or sell them. [OWNERSHIP_CHART-10982]

Finally, payments toward the remaining US$45–55M balance still owed to Revolve regarding the ENGIE sale could boost its stock.

Ownership and Share Structure

About 60% of the company is owned by insiders and management, Revolve said.

Top shareholders include Joseph O'Farrell with 13.21%, Roger Norwich with 12.15%, the CEO and Director Stephen Dalton with 6.01%, President and Director Omar Bojorquez with 4.82%, and Jonathan Clare with 1.84%, according to Reuters and the company.

The rest is retail.

Revolve has a market cap of CA$17.96M. It has 63.04M outstanding shares and 38.75M free float traded shares. Its 52-week high and low are CA$0.50 and CA$0.21 per share, respectively.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Revolve Renewable Power Corp.
2. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
3. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

( Companies Mentioned: TSXV:REVV;OTCQB:REVVF, )

Full Text:

Many wild southern sea otters in California are infected with the parasite Toxoplasma gondii, yet the infection is fatal for only a fraction of sea otters, which has long puzzled the scientific community. A National Science Foundation-funded study identifies the parasite's specific strains that are killing southern sea otters, tracing them back to a bobcat and feral domestic cats from nearby watersheds. The study marks the first time a genetic link has been clearly established between the Toxoplasma strains in felid hosts and parasites causing fatal disease in marine wildlife. The study's results highlight how infectious agents like Toxoplasma can spread from cat feces on land to the sea, leading to detrimental impacts on marine wildlife.

Image credit: Trina Wood/UC Davis

Global financial platform Adyen has announced that it enabled...

Our technical support group recently received a request for a tool that would convert IBM System/360 hexadecimal floating point numbers to the IEEE-754 format. I am probably the only one left at MathWorks that actually used IBM mainframe computers. I thought we had seen the last of hexadecimal arithmetic years ago. But, it turns out that the hexadecimal floating point format is alive and well.... read more >>

Floating point arithmetic doesn't get the respect it deserves. Many people consider it mysterious, fuzzy, unpredictable. These misgivings often occur in discussion of vector sums. Our provocatively named SuperSum is intended to calm these fears.... read more >>

Many hospitals around the country, including Medstar Washington Hospital in Washington DC., have started sharing their prices online in compliance with a recent federal rule.; Credit: DANIEL SLIM/AFP via Getty Images

A colonoscopy might cost you or your insurer a few hundred dollars — or several thousand, depending on which hospital or insurer you use.

Long hidden, such price variations are supposed to be available in stark black and white under a Trump administration price transparency rule that took effect at the start of this year. It requires hospitals to post a range of actual prices — everything from the rates they offer cash-paying customers to costs negotiated with insurers.

Many have complied.

But some hospitals bury the data deep on their websites or have not included all the categories of prices required, according to industry analysts. A sizable minority of hospitals have not disclosed the information at all.

While imperfect and potentially of limited use right now to the average consumer, the disclosures that are available illustrate the huge differences in prices — nationally, regionally and within the same hospital. But they're challenging for consumers and employers to use, giving a boost to a cottage industry that analyzes the data.

While it's still an unanswered question whether price transparency will lead to overall lower prices, KHN took a dive into the initial trove of data to see what it reveals. Here are five takeaways from the newly public data and tips for how you might be able to use it to your benefit

1) As expected, prices are all over the map

The idea behind the requirement to release prices is that the transparency may prompt consumers to shop around, weighing cost and quality. Perhaps they could save a few hundred dollars by getting their surgery or imaging test across town instead of at the nearby clinic or hospital.

Under the Trump-era rule, hospitals must post what they accept from all insurers for thousands of line items, including each drug, procedure or treatment they provide. In addition, hospitals must present this in a format easily readable by computers and include a consumer-friendly separate listing of 300 "shoppable" services, bundling the full price a hospital accepts for a given treatment, such as having a baby or getting a hip replacement.

The negotiated rates now being posted publicly often show an individual hospital accepting a wide range of prices for the same service, depending on the insurer, often based on how much negotiating power each has in a market.

In some cases, the cash-only price is less than what insurers pay. And prices may vary widely within the same city or region.

In Virginia, for example, the average price of a diagnostic colonoscopy is $2,763, but the range across the state is from $208 to $10,563, according to a database aggregated by San Diego-based Turquoise Health, one of the new firms looking to market the data to businesses, while offering some information free of charge to patients.

2) Patients can look up the information, but it's incomplete

Patients can try to find the price information themselves by searching hospital websites, but even locating the correct tab on a hospital's website is tricky.

Typically, consumers don't comparison-shop, preferring to choose convenience or the provider their doctor recommends. A recent Peterson-KFF Health System Tracker brief, for instance, found that 85% of adults said they had not researched online the price of a hospital treatment.

And hospitals say the transparency push alone won't help consumers much, because each patient's situation is different and may vary from the average— and individual deductibles and insurance plans complicate matters.

But if you do want to try, here's one tip: "You can Google the hospital name and the words 'price transparency' and see where that takes you," says Caitlin Sheetz, director and head of analytics at the consulting firm ADVI Health in the Washington, D.C., metro area.

Typing in "MedStar Health hospital transparency," for example, likely points to the MedStar Washington Hospital Center's "price transparency disclosure" page, with a link to its full list of prices, as well as its separate list of 300 shoppable services.

By clicking on the list of shoppable services, consumers can download an Excel file. Searching it for "colonoscopy" pulls up several variations of the procedure, along with prices for different insurers, such as Aetna and Cigna, but a "not available" designation for the cash-only price. The file explains that MedStar does not have a standard cash price but makes determinations case by case.

Performing the same Google search for the nearby Inova health system results in less useful information.

Inova's website links to a long list of thousands of charges, which are not the discounts negotiated by insurers, and the list is not easily searchable. The website advises those who are not Inova patients or who would like to create their own estimate to log into the hospitals' "My Chart" system, but a search on that for "colonoscopy" failed to produce any data.

3) Third-party firms are trying to make searching prices simpler – and cash in

Because of the difficulty of navigating these websites — or locating the negotiated prices once there — some consumers may turn to sites like Turquoise. Another such firm is Health Cost Labs, which will have pricing information for 2,300 hospitals in its database when it goes live July 1.

Doing a similar search for "colonoscopy" on Turquoise shows the prices at MedStar by insurer, but the process is still complicated. First, a consumer must select the "health system" button from the website's menu of options, click on "surgical procedures," then click again on "digestive" to get to it.

There is no similar information for Inova because the hospital has not yet made its data accessible in a computer-friendly format, said Chris Severn, CEO of Turquoise.

Inova spokesperson Tracy Connell said in a written statement that the health system will create personalized estimates for patients and is "currently working to post information on negotiated prices and discounts on services."

Firms like Turquoise and Health Cost Labs aim to sell the data gathered from hospitals nationally to insurers, employers and others. In turn, those groups may use it in negotiations with hospitals over future prices. While that may drive down prices in areas with a lot of competition, it might do the opposite where there are few hospitals to choose from, or in situations where a hospital raises its prices to match competitors.

4) Consumers could use this data to negotiate, especially if they're paying cash

For consumers who go the distance and can find price data from their hospitals, it may prove helpful in certain situations:

• Patients who are paying cash or who have unmet deductibles may want to compare prices among hospitals to see if driving farther could save them money.
• Uninsured patients could ask the hospital for the cash price or attempt to negotiate for the lowest amount the facility accepts from insurers.
• Insured patients who get a bill for out-of-network care may find the information helpful because it could empower them to negotiate a discount off the hospitals' gross charges for that care.

While there's no guarantee of success, "if you are uninsured or out of network, you could point to some of those prices and say, 'That's what I want,'" says Barak Richman, a contract law expert and professor of law at Duke University School of Law.

But the data may not help insured patients who notice their prices are higher than those negotiated by other insurers.

In those cases, legal experts say the insured patients are unlikely to get a bill changed because they have a contract with that insurer, which has negotiated the price with their contracted hospitals.

"Legally, a contract is a contract," says Mark Hall, a health law professor at Wake Forest University.

Richman agrees.

"You can't say, 'Well, you charged that person less,'" he notes, but neither can they say they'll charge you more.

Getting the data, however, relies on the hospital having posted it.

5) Hospitals still aren't really on board

When it comes to compliance, "we're seeing the range of the spectrum," says Jeffrey Leibach, a partner at the consulting firm Guidehouse, which found earlier this year that about 60% of 1,000 hospitals surveyed had posted at least some data, but 30% had reported nothing at all.

Many in the hospital industry have long fought transparency efforts, even filing a lawsuit seeking to block the new rule. The suit was dismissed by a federal judge last year.

They argue the rule is unclear and overly burdensome. Additionally, hospitals haven't wanted their prices exposed, knowing that competitors might then adjust theirs, or health plans could demand lower rates. Conversely, lower-cost hospitals might decide to raise prices to match competitors.

The rule stems from requirements in the Affordable Care Act. The Obama administration required hospitals to post their chargemaster rates, which are less useful because they are generally inflated, hospital-set amounts that are almost never what is actually paid.

Insurers and hospitals are also bracing for next year when even more data is set to come online. Insurers will be required to post negotiated prices for medical care across a broader range of facilities, including clinics and doctors' offices.

In May, the Centers for Medicare & Medicaid Services sent letters to some of the hospitals that have not complied, giving them 90 days to do so or potentially face penalties, including a $300-a-day fine.

"A lot of members say until hospitals are fully compliant, our ability to use the data is limited," says Shawn Gremminger, director of health policy at the Purchaser Business Group on Health, a coalition of large employers.

His group and others have called for increasing the penalty for noncomplying hospitals from $300 a day to $300 a bed per day, so "the fine would be bigger as the hospital gets bigger," Gremminger says. "That's the kind of thing they take seriously."

Already, though, employers or insurers are eyeing the hospital data as leverage in negotiations, says Severn, Turquoise's CEO. Conversely, some employers may use it to fire their insurers if the rates they're paying are substantially more than those agreed to by other carriers.

"It will piss off anyone who is overpaying for health care, which happens for various reasons," he says.

KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. Together with Policy Analysis and Polling, KHN is one of the three major operating programs at KFF (Kaiser Family Foundation).

This content is from Southern California Public Radio. View the original story at SCPR.org.

People rest while riding a Los Angeles Metro Rail train amid the coronavirus pandemic on April 1, 2020 in Los Angeles, California.; Credit: Mario Tama/Getty Images

Despite the racial reckoning going on in America right now, and despite the fact that attitudes towards race, inclusion and representation are different now than they were 30 years ago, new research from UC Berkeley shows that a large majority of American metro areas are more segregated now than they were in 1990. The new report from Berkeley’s Institute covers a number of topic areas, but among the key findings were from the national segregation report component of the project, which found Los Angeles to be the sixth-most segregated metro area with more than 200,000 people.

Today on AirTalk, we’ll talk with the lead researcher on the new report and a local historian to talk about how we see the findings of the report play out in Southern California.

Guests:

Stephen Menendian, assistant director and director of research at the Othering & Belonging Institute at UC Berkeley, which works to identify and eliminate the barriers to an inclusive, just, and sustainable society in order to create transformative change; he tweets @SMenendian

Eric Avila, professor of history, urban planning, and Chicano/a studies at UCLA

This content is from Southern California Public Radio. View the original story at SCPR.org.

A homeless encampment is pictured at Venice Beach, on June 30, 2021 in Venice, California, where an initiative began this week offering people in homeless encampments a voluntary path to permanent housing.; Credit: FREDERIC J. BROWN/AFP via Getty Images

The majority of unhoused women across the nation — 57% according to recent data — say domestic violence is the direct cause of losing their permanent home. 

In L.A, almost 40% of women who are homeless say they’ve experienced abuse in the last 12 months.

The choice they’ve been forced to make: Stay in danger with their abusers — or escape, with nowhere to go.

“It’s like jumping from a burning building but there’s no net to catch you,” said Nikki Brown, a survivor and advocate.

There are many, complex reasons why survivors become homeless. Shame is one of them. Yet studies show that one in three women experience some form of intimate partner abuse in their lives. So why don’t we talk about it more?

“It's the greatest secret that's super common and nobody wants to admit it,” said Brown. “There are so many complicated circumstances that make it really hard to leave. And when you can't leave, that element of shame and blame is the thing that makes it so hard to talk about.”

Today on AirTalk, we’re learning more about reporter Julia Paskin’s series Pushed Out, on domestic violence and homelessness in Los Angeles. Do you have an experience you want to share? Give us a call at 866-893-5722.

Guests:

Julia Paskin, KPCC producer and reporter who created the “Pushed Out” series; she tweets @JuliaPaskinInc

Amy Turk, CEO of Downtown Women’s Center, which advocates and offers services for women experiencing homelessness and formerly homeless women; she tweets @AmyFTurk

Nikki Brown, staff attorney at Community Legal Aid SoCal, where she has clients that are domestic violence survivors

This content is from Southern California Public Radio. View the original story at SCPR.org.

The USGS is pleased to announce the release of new US Topo maps for Puerto Rico and the U.S. Virgin Islands. These updated topographic maps offer valuable, current geographic information for residents, visitors, and professionals, providing essential resources for communities in these areas.

Dr. Jill Baron, Director of the Powell Center, will present a webinar on how to develop a strong proposal for Working Group on November 19th, 2024, at 11am MT/1pm ET.

Lawmakers in Washington, D.C., have reached a preliminary, bipartisan agreement on police reform after months of closely watched debate on the topic.

Sens. Tim Scott, R-S.C., and Cory Booker, D-N.J., and Rep. Karen Bass, D-Calif., announced the agreement on Thursday evening.

"After months of working in good faith, we have reached an agreement on a framework addressing the major issues for bipartisan police reform," the lawmakers said in a joint statement.

"There is still more work to be done on the final bill, and nothing is agreed to until everything is agreed to. Over the next few weeks we look forward to continuing our work toward getting a finalized proposal across the finish line."

The exact details of the plan were not immediately clear.

The issue of reforming qualified immunity, to make it easier to sue police officers over allegations of brutality, had been a sticking point in negotiations. The police use of chokeholds was another debated provision.

The effort to reform U.S. policing comes after several years of increasing pressure to better understand and regulate the way officers interact with the communities they patrol.

The high-profile deaths of several Black people — many unarmed — at the hands of police — who have in some notable instances been white — have been the catalyst for the police reform movement.

The Democratic-led House had approved the George Floyd Justice in Policing Act — named after one of those Black people killed by police — in early March, and President Biden had hoped Congress would pass the reform effort by the first anniversary of Floyd's death in late May.

But Bass had said then that getting "a substantive piece of legislation" is "far more important than a specific date."

Floyd's murderer, former Minneapolis police officer Derek Chauvin, is set to be sentenced to prison on Friday.

White House press secretary Jen Psaki said in a statement Thursday that Biden "is grateful to Rep. Bass, Sen. Booker, and Sen. Scott for all of their hard work on police reform, and he looks forward to collaborating with them on the path ahead."

The topic of police reform has divided the nation across party lines, with progressives accusing the right of seeking to maintain an antiquated and all-too-powerful law enforcement apparatus. Conservatives say the left has blamed the actions of some officers on the institution itself, turning the topic of police support and "blue lives" into more ammunition for the ongoing culture war.

This content is from Southern California Public Radio. View the original story at SCPR.org.

According to one new account of the Trump presidency, even telling the story of President Trump's Covid diagnosis was difficult due to the chaos in the white house. Here, Trump removes his protective mask after being discharged from the Walter Reed National Military Medical Center with Covid-19.; Credit: Bloomberg/Bloomberg via Getty Images

When the Wall Street Journal's Michael Bender wrote his book about Donald Trump's 2020 defeat, one section stuck out as particularly difficult: telling the story of what Bender dubbed "Hell Week-And-A-Half."​

"It was the ten days in 2020 that started with the super spreader event in the Rose Garden, included the Trump's disastrous debate with Joe Biden in Cleveland, and then Trump himself obviously testing positive for COVID a few days later," Bender said.

It's not just that it was a lot to fold together; it's that simply figuring out what happened was maddening.​

"How early he tested positive, how sick he was during that time — I mean, these are serious questions with national security implications that very few people knew or had firsthand knowledge of, and I had competing versions from senior officials, serious people who all were telling me different versions of that story," he said.

Bender's Frankly, We Did Win This Election is one of many books trying to pull order from Trump's chaos, and that struggle to discern the truth, he explains, is itself emblematic of the Trump administration.​

"The deception wasn't just with the public. It was literally from person to person inside the West Wing," he said. "And that's the story — not necessarily worrying about exactly what happened, which will have to come out at some later point, if it ever does."

Former officials are judging Trump's election lies and pandemic response poorly

Judging from the excerpts that have been released, this first wave of post-Trump-presidency books is filled with behind-closed-doors details — like, for example, how gravely ill Trump was with COVID-19, or former Attorney General William Barr's blunt assessment about Trump's claims of a rigged election: "​My suspicion all the way along was that there was nothing there. That it was all bulls***," as ABC's Jonathan Karl recounts.

But the challenge of recounting this chapter of American history is not just about recounting news-making moments — the racist statements, the allegations of sexual assault, the impeachments — but making sense of it.​

Yasmeen Abutaleb, who coauthored the forthcoming Nightmare Scenario with her Washington Post colleague Damian Paletta, agreed that it was hard to discern the truth from dozens of conflicting stories from within the White House.

But that made it all the more striking when they did find consensus on the Trump White House's coronavirus response. "Of the more than 180 people we spoke to, there wasn't a single one who defended the collective response," she said.

Writing this book, she added, allowed her and Paletta to come away with a clearer assessment of the Trump White House's pandemic response than they gleaned from their day-to-day coverage last year.

"Coronavirus was going to be a challenge no matter who was in charge," she said. "But when we looked at the number of opportunities there were to turn the response around, many of which we didn't know about at the time or couldn't learn it at the time, I think we were shocked at the number of opportunities there were and how they weren't taken."

In addition to the challenge of telling complete, ordered stories of a chaotic presidency, there is also the challenge of placing that presidency into historical context, says Princeton presidential historian Julian Zelizer. He's working with a team of historians to pull together a history of the Trump administration.

"Why did America's political system have room for so much chaos over a four year period? Which is this big puzzle I don't think everyone's totally grappled with," he said.

It's not just journalists and historians. Trump-administration insiders will try to explain their place in history. That's according to Keith Urbahn, a co-founder of Javelin, a literary agency that represented Bender, former UN ambassador John Bolton, and former FBI director James Comey, with more to come.​

"I think it does require for people who worked in the Trump presidency to wrestle with some of the moral compromises that they had to make by serving in that administration," he said.

Post-Trump chaos is rippling through the publishing world

Writing the history of a leaky, live-tweeted presidency has been unusual for a variety of additional reasons. There's book industry tumult — Simon and Schuster employees protested the publishing giant over printing former Vice President Mike Pence's book.

In addition, Trump could still run for president again, which may be why he has given at least 22 book interviews, Axios recently reported. (He has also said he is writing the "book of all books," though some major publishers are hesitant about publishing it, Politico has reported.)

The Trump era was also unusual for the book industry in another way.

"We can honestly say that the four years of the Trump administration were four of the strongest years cumulatively for political books since we've been tracking books, which started in 2001," said Kristen McLean, executive director and industry analyst at market research firm NPD.

Now, however, those sales moving back towards a pre-Trump normal — political book sales are down 60% from the second half of 2020, McLean said.

But that doesn't mean interest will disappear, according to Javelin co-founder Matt Latimer.​

"For example, next year there are a dozen or more books coming out about President Nixon," he said. "I mean, I think long after we're all gone, people are going to be trying to figure out what the hell this was all about."

It's been 47 years since Nixon resigned. By that same math, we'll be reading new Trump books into the late 2060s — and probably beyond.

This content is from Southern California Public Radio. View the original story at SCPR.org.

"This is a petty, partisan power grab that is absolutely retaliation towards my office," Arizona Democratic Secretary of State Katie Hobbs says of the new law.; Credit: Ross D. Franklin/AP

Arizona Republicans have stripped the secretary of state's office — currently held by a Democrat — of the right to defend the state's election laws in court, or choose not to, a change enacted as part of Arizona's newly signed budget.

The spending blueprint that Gov. Doug Ducey signed into law Wednesday declares that the attorney general — currently a position occupied by Republican Mark Brnovich — has sole authority over election-related litigation.

If the secretary of state and attorney general were to disagree over a legal strategy when Arizona election laws are challenged, the new law states that "the authority of the attorney general to defend the law is paramount."

Republicans also adopted language stating it's their intent for the law to apply through Jan. 2, 2023, coinciding with the end of Democrat Katie Hobbs' term as secretary of state.

Hobbs, the top election official in Arizona who's now running for governor, says her lawyers are looking at whether this change violates the Arizona Constitution.

"This is a petty, partisan power grab that is absolutely retaliation towards my office," Hobbs said. "It's clear by the fact that it ends when my term ends. ... It is at best legally questionable, but at worst, likely unconstitutional."

Republicans have generally cast the law as a cost-saving measure, citing Hobbs and Brnovich's frequent disagreements over how to defend state election laws that have been challenged in court. In 2020, Hobbs filed complaints with the state bar against Brnovich and other lawyers in his office.

Other election provisions in the budget

The budget includes a number of other election provisions, and it comes weeks after Republicans enacted new restrictions on early voting in the state, and as a controversial review of 2020 election results in Maricopa County continues.

Here are some of the other election-related measures in the budget:

• New laws could soon require watermarks, QR codes and other security measures to be printed on ballots.
• There's a new mandate to inspect state and county voter registration databases and create a report on voters who cast federal-only ballots — an option available to Arizonans who don't show proof of citizenship to register to vote in the state, but are still allowed to register under federal law.
• And a new task force would investigate alleged social media bias as an unreported in-kind political contribution.

The ballot security measures, though not mandated by law in the budget, have the potential to be the most cumbersome and costly requirement for county election officials to implement.

The budget amendment provides a list of 10 "ballot fraud countermeasures" for counties to choose from — features like holographic foil, background designs similar to those found on banknotes and ultraviolet or infrared ink. If mandated, counties would have to implement any combination of at least three features from the list on their ballots. The budget provides $12 million to pay for those features, to be split among Arizona's 15 counties.

"By everyone's admission, there is only one company that can do any of this," said Jennifer Marson, executive director of the Arizona Association of Counties. "And so now, we can't have a competitive bid process or a traditional procurement process at the county or state level to use these countermeasures because we're locked into one company."

That company is Authentix, a Texas-based firm that provided Republican Rep. Mark Finchem with a sample ballot that included watermarks, QR codes and other security measures. Finchem had the sample ballot on display at the Capitol in March. According to the Yellow Sheet Report, it could be five times more expensive to print ballots with those security measures as it is to print paper ballots currently in use.

Marson said Finchem has acknowledged the security levels required of companies in the budget amendment could only be met by Authentix, and has vowed to mandate the ballot security measures in the "very near future."

Finchem defended the company in a brief email. He wrote that Authentix "offers these countermeasures to governments around the world for document and tax stamp security."

As the budget was being considered, Democrats like Sen. Tony Navarrete said the amendment is part of a broad effort to solidify conspiracy theories of election fraud.

"It's important for us to make sure we vote down conspiracy-laced amendments that are going to hurt the integrity of our election system in the state of Arizona and encourage other states to have these bad copycat laws spread like wildfire," he said.

This content is from Southern California Public Radio. View the original story at SCPR.org.

A waitress wears a face mask while serving at Langer's Delicatessen-Restaurant in Los Angeles on June 15.; Credit: Frederic J. Brown/AFP via Getty Images

Normal is not easily defined.

The past 15 months, though, have certainly been anything but.

Americans are starting to believe a "sense of normal" is approaching fairly soon, however, according to a new NPR/PBS NewsHour/Marist survey. The poll also found that with the coronavirus receding in this country, mask-wearing is declining and Americans are going out more. But they remain cautious about being in large crowds.

As the country continues to open up, more focus turns to the economy, which cratered during the beginning of the pandemic last year. And Americans are split by race, gender and politics on whether President Biden's ambitious policies are helping or not.

Race, gender, party divides on Biden and the economy

Three months ago, in a similar survey, 49% of adults said the president's policies were strengthening the economy, while 44% said they were weakening it.

Now, that's declined a net of 6 points, as 44% of respondents in the new poll say Biden's policies have strengthened the economy and 45% say the opposite. The percentage who were unsure also jumped 4 points. It's all a little bit of a warning sign for Biden, as he pushes for two large — and expensive — spending packages.

There are significant splits by race and gender:

• Just 39% of whites said Biden's policies have strengthened the economy, but 52% of people of color say they have.
• 54% of independent men say his policies have weakened the economy, while 56% of independent women say they've strengthened it. 
• 45% of white male college grads say Biden has strengthened the economy, but a significantly higher 64% of white women with college degrees said so.

Inflation vs. wages by party

A quarter of Americans rank inflation as the U.S. economy's top concern. That's followed by wages, unemployment, housing costs, labor shortages, gas prices and interest rates.

But there's a sharp political divide on the question. Republicans and independents rank inflation as their top concern, while for Democrats, it was wages. Just 4% of Republicans said wages were their top concern.

Return to "normal"

Americans are growing increasingly optimistic about when life will return to a "sense of normal," as the survey labels it.

In April, three-quarters of Americans said they believe it will take six months or more. Now, it's just half. About a quarter (27%) say it will be less than six months, up from 15% two months ago.

People are also growing more comfortable doing certain things, saying they're:

• dining out at restaurants (78%) and 
• visiting unvaccinated friends and family (75%).

But they are not as comfortable doing others:

• almost 7-in-10 are not going out to bars; 
• about two-thirds are not attending live concerts or sporting events (65%);
• and a majority have also not resumed going to in-person religious services (54%).

COVID-19 vaccines and going back to work

While half say they are concerned about another coronavirus surge, almost 9-in-10 U.S. adults with jobs say they are at least somewhat comfortable returning to work.

Notably, a majority (57%) of those with jobs do not believe employers should require COVID-19 vaccines as a condition to return to in-person work.

More than a quarter of Americans say they will not get vaccinated. The most resistant to getting vaccinated continue to be supporters of former President Donald Trump. Half of them say they won't get the shot, the highest of any group surveyed. Trump has touted the vaccine and got it himself.

Since Centers for Disease Control and Prevention guidelines came out, noting that Americans who have been vaccinated can largely set masks aside, there's been a double-digit decline in those saying they wear a mask even when it's not required.

There's also been a double-digit increase in those saying they generally do not wear a mask. In May, 49% said they wore masks even when it was not required. Now, that's just 36%.

One-in-five said they generally do not wear masks. Two months ago, it was less than one-in-10.

Affordability, not coronavirus, limiting vacations

Speaking of getting back to normal, a majority of Americans say they plan to take a vacation this summer.

But of the significant minority (45%) who say they aren't taking one, almost three times as many cited affordability (35%) as the main reason for not going, as opposed to concerns about COVID-19 (12%).

Methodology: The poll of 1,115 U.S. adults was conducted using live telephone interviewers from June 22 through June 29. Survey questions were available in English or Spanish. The full sample has a margin of error of plus or minus 3.7 percentage points, with larger margins of error for smaller group subsets.

This content is from Southern California Public Radio. View the original story at SCPR.org.

A voter marks his ballot at a polling place on Nov. 3, 2020, in Richland, Iowa. A new poll finds ensuring access to voting is more important than tamping down voter fraud for most Americans.; Credit: Mario Tama/Getty Images

A majority of Americans believes ensuring access to voting is more important than rooting out fraud, the latest NPR/PBS NewsHour/Marist survey finds.

At the same time, there was broad agreement that people should have to show identification when they go to the polls.

Two-thirds of Americans also believe democracy is "under threat," but likely for very different reasons.

"For Democrats, Jan. 6 undoubtedly looms large," said Lee Miringoff, director of the Marist Institute for Public Opinion, referring to the violence and insurrection at the Capitol, "while, for Republicans, it's more likely about Trump and his claims of a rigged election."

Voting access vs. fraud

By a 56%-41% margin, survey respondents said making sure that everyone who wants to vote can do so is a bigger concern than making sure that no one who is ineligible votes.

But there were wide differences by political party and by race.

Among Democrats, almost 9 in 10 said access was more important, but almost three-quarters of Republicans said it was making sure no one votes who isn't eligible.

By race, a slim majority of whites said ensuring everyone who wants to vote can was most important, but almost two-thirds of nonwhites said so.

Photo ID is popular

Nearly 8 in 10 Americans said they believe voters should be required to show government-issued photo identification whenever they vote.

Majorities of Democrats, Republicans, independents, whites and nonwhites all said so. Democrats were far lower, though, with 57% believing photo ID should be required.

Biden holding steady

President Biden gets a 50% job approval rating, largely unchanged from last month. There is a sharp partisan divide with 9 in 10 Democrats approving, and more than 8 in 10 Republicans disapproving.

Biden continues to get his highest ratings when it comes to his handling of the coronavirus pandemic, and his economic approval is holding steady. But Americans have less confidence in his handling of foreign policy, especially immigration. His approval on immigration ticked up slightly from March when it was last measured in the poll.

By a 50%-43% margin, respondents said Biden had strengthened America's role on the world stage.

Americans are split about whether the country is headed in the right direction or not — 49% said it wasn't, 47% said it was. It's an improvement, however, from right after the Jan. 6 insurrection when three-quarters said the country was on the wrong track.

The tone has gotten worse in Washington since Biden was elected, 41% said, but that's better than the two-thirds who said so consistently during the Trump years.

Methodology: The poll of 1,115 U.S. adults was conducted using live telephone interviewers from June 22-29. Survey questions were available in English or Spanish. The full sample has a margin of error of plus or minus 3.7 percentage points with larger margins of error for smaller group subsets.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Actor Dwayne Johnson (L) and Simone Alexandra Johnson attend the People's Choice Awards 2017 at Microsoft Theater on January 18, 2017 in Los Angeles, California. ; Credit: Christopher Polk

When Dwayne "The Rock" Johnson debuted his Hollywood persona in World Wrestling Entertainment in 2003, he was two years removed from his first successful protagonist role in "The Scorpion King" and on the heels of more film success with roles in "The Rundown" and "Walking Tall." 

Little did anyone foresee that "Hollywood" Rock would buoy the overall representation for Asian and Pacific Islanders in popular film for the next 20 years.

Last week, the USC Annenberg Inclusion Initiative released a report documenting the prevalence of Asian and Pacific Islanders both on-and off-screen across the top-grossing films each year from 2007 to 2019.  Of the 1,300 films examined, only 44 featured API actors playing lead roles, nearly a third of which were played by Johnson. 

The report offers more staggering statistics:

• In 2019, over a quarter of API characters in the top-grossing films died. Most died by drowning, explosions, stabbing or suicides

• Of the over 51,000 speaking characters in the 1,300 films examined, only 6% were Asian, Asian American or Native Hawaiian/Pacific Islanders

• Only 50 of the 1,447 directors in the 1,300 films examined were of API heritage.

• In 2019, 67% of API characters played stereotyped roles

The release of this report comes at a time of rising anti-Asian hate crimes nationally, and the authors of the report believe the portrayal of Asian and Pacific Islanders in mass media contributes to that. Today on FilmWeek, we delve into the study's findings and discuss the history of API filmmakers and actors in Hollywood.

Guests: 

Nancy Wang Yuen, professor of sociology at Biola University in La Mirada; she is co-author of “The Prevalence and Portrayal of Asian and Pacific Islanders Across 1,300 Popular Films”; she tweets @nancywyeun

Justin Chang, film critic for the Los Angeles Times and NPR’s Fresh Air; he tweets @JustinCChang

This content is from Southern California Public Radio. View the original story at SCPR.org.

Vancouver-based minerals explorer Prosper Gold Corp. (TSVX: PGF; OTCQB: PGXFF) is focused on its district-scale Cyprus copper-gold project in north-central British Columbia. One analyst says the results of a recent geophysical survey put the stock in an excellent position.

Emerita Resources Corp. (EMO:TSX.V; EMOTF:OTCQB; LLJA:FSE) announces results from a metallurgical testing program at its wholly-owned Iberian Belt West (IBW) project in Spain. Read why one expert says the company is in "the right place to be."

Global Analyst Adrian Day reviews financials and preliminary reports from some major resource companies as well as developments at others. He also answers a reader's question on Newmont: is it a good buy after the sharp drop after its earnings?

Giant Mining Corp. (CSE: BFG; OTC:BFGFF; FWB:YW5) announced the expansion of its surface exploration program at the Majuba Hill copper-silver deposit in Pershing County, Nevada. Read more to learn about the promising high-grade copper findings and the project's potential impact on the EV and renewable energy sectors.

Full Text:

Bridges make travel faster and more convenient, but, in an earthquake, these structures are subject to forces that can cause extensive damage and make them unsafe. Now civil and environmental engineer Petros Sideris of Texas A&M University is leading a National Science Foundation (NSF)-funded research project to investigate the performance of hybrid sliding-rocking (HSR) columns. HSR columns provide the same support as conventional bridge infrastructure columns but are more earthquake-resistant. HSR columns are a series of individual concrete segments held together by steel cables that allow for controlled sliding and rocking. This allows the columns to shift without damage, while post-tensioning strands ensure that at the end of an earthquake the columns are pushed back to their original position. Conventional bridges are cast-in-place monolithic concrete elements that are strong but inflexible. Structural damage in these bridge columns, typically caused by a natural disaster, often forces a bridge to close until repairs are completed. But bridges with HSR columns can withstand large earthquakes with minimal damage and require minor repairs, likely without bridge closures. Such infrastructure helps with post-disaster response and recovery and can save thousands in taxpayer dollars. In an earthquake, HSR columns provide "multiple advantages to the public," Sideris said. "By preventing bridge damage, we can maintain access to affected areas immediately after an event for response teams to be easily deployed, and help affected communities recover faster. In mitigating losses related to post-event bridge repairs and bridge closures, more funds can be potentially directed to supporting the recovery of the affected communities." According to Joy Pauschke, NSF program director for natural hazards engineering, "NSF invests in fundamental engineering research so that, in the future, the nation's infrastructure can be more resilient to earthquakes, hurricanes, and other forces of nature."

Image credit: Texas A&M University

Source: Andrew Fein 10/23/2024

H.C. Wainwright & Co. analysts Andrew S. Fein, Matthew Caufield, Dr. Andres Y. Maldonado, and Dr. Ananda Ghosh, in a research report published on October 23, 2024, maintained a Buy rating on DBV Technologies SA (DBVT:NASDAQ) while raising their price target to US$7.00 from US$5.00. The report follows DBV's announcement of regulatory clarity regarding the path forward for its Viaskin Peanut patch.

The analysts highlighted the significance of the FDA agreement, stating, "DBV Technologies has reached an agreement with the FDA regarding the regulatory pathway for the Viaskin Peanut patch in toddlers aged one to three, under the Accelerated Approval pathway."

Regarding the company's development timeline, the analysts noted, "The Biologics License Application (BLA) submission for Viaskin Peanut in this age group is expected to be supported by positive efficacy and safety data from DBV's completed EPITOPE Phase 3 study, as well as additional safety data from the upcoming six-month COMFORT Toddlers supplemental safety study, which is expected to begin in 2Q25."

The report emphasized the strength of DBV's regulatory position, stating, "The FDA has stated that DBV has already satisfied two of the three criteria: the product treats a serious condition, and the product candidate provides a meaningful advantage over available therapies."

The analysts also highlighted progress in Europe, noting, "The EMA confirmed that the successfully completed EPITOPE Phase 3 efficacy and safety trial in the one to three-year-old population, along with positive results from the VITESSE study in the four to seven-year-old population, and a new safety study using the modified circular patch in one to three-year-olds, could support an MAA for the one to seven-year-old indication with the modified patch."

The analysts' valuation methodology for DBV Technologies is based on a composite approach. They explained, "Our US$7 price target is based on an equally weighted composite of: (a) US$5.10/share, as a 20x multiple of taxed and diluted FY34 GAAP EPS of US$5.13 discounted back to FY24 at 35%; and (b) an NPV of US$8.52/share with a 13% discount rate and 1% growth rate."

The report included commercial projections, with the analysts stating, "We continue to model initial approval in 2027, with projected initial sales of US$17.5M, growing to US$1,182.8M by 2034."

The analysts also outlined several risk factors, including potential clinical study failures, regulatory approval challenges, and market size uncertainties.

In conclusion, H.C. Wainwright & Co.'s increased price target to US$7 reflects growing confidence in DBV Technologies' regulatory pathway for the Viaskin Peanut patch. The share price at the time of the report of US$0.70 represents a potential return of approximately 900% to the analysts' target price, highlighting the significant upside potential if the company successfully navigates the regulatory process and commercializes its product.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co. DBV Technologies S.A., October 23, 2024

Important Disclaimers This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet.

H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility.

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Andrew S. Fein, Matthew Caufield, Andres Y. Maldonado, PhD and Ananda Ghosh, PhD , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of DBV Technologies S.A. (including, without limitation, any option, right, warrant, future, long or short position). As of September 30, 2024 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of DBV Technologies S.A.

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report. The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The firm or its affiliates received compensation from DBV Technologies S.A. for non-investment banking services in the previous 12 months. The Firm or its affiliates did not receive compensation from DBV Technologies S.A. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in DBV Technologies S.A. as of the date of this research report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

( Companies Mentioned: DBVT:NASDAQ, )

Source: Dr. Douglas Loe 10/31/2024

Leede Financial analysts Dr. Douglas Loe and Siew Ching Yeo, in a research report published on October 30, 2024, maintained their Speculative Buy rating on ProMIS Neurosciences Inc. (PMN:TSX; PMN:NCM) with a price target of US$9.50. The report follows ProMIS's presentation of interim Phase I data for PMN310, its Alzheimer's disease (AD) candidate, at the Clinical Trials on Alzheimer's Disease (CTAD) conference.

The analysts highlighted the positive safety and pharmacokinetic (PK) data, stating, "We were encouraged (though not overly surprised) to see that the mAb was well-tolerated at all five test doses ranging from 2.5mg/kg-to-40mg/kg." They added, "PK analysis of all of these patient cohorts in this single-ascending dose (SAD) trial suggests that once-monthly dosing may be sufficient to sustain mAb levels both in plasma and in cerebrospinal fluid over time."

Regarding dosing efficacy, the analysts noted, "Importantly, ProMIS indicated in the Jul/24 update that even at 2.5mg/kg dosing, PMN310 levels in CSF were over 100x higher than predicted to be necessary to bind to all beta-amyloid oligomers that could accumulate in CSF in diseased patients."

The analysts emphasized the significance of recent industry developments, particularly AbbVie's acquisition of Aliada Therapeutics, stating, "AbbVie's tangible interest in Phase I-stage AD assets shows us that ProMIS could itself be attractive to future suitors if/when it can document direct impact on cognitive impairment in diseased patients."

The report highlighted ProMIS's financial position following its recent equity offering, noting that the company raised US$30.3M with multiple layers of warrant coverage tied to development milestones.

Leede Financial's valuation methodology combines multiple approaches. The analysts explained, "We are maintaining our Speculative Buy rating and one-year PT of US$9.50 on PMN, with our valuation still based on NPV (30% discount rate) and multiples of our F2029 EBITDA/fd EPS forecasts."

They added, "By direct comparison to Aliada's US$1.4B value, PMN shares would notionally be valued on a fully-diluted basis at US$17.65/shr."

In conclusion, Leede Financial's maintenance of their Speculative Buy rating and US$9.50 price target reflects confidence in ProMIS's development of PMN310 and its potential in the Alzheimer's disease market. The share price at the time of the report of US$1.03 represents a potential return of approximately 822% to the analysts' target price, highlighting the significant upside potential if the company's clinical development plans prove successful.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS Neurosciences Inc.
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Leede Financial Inc., ProMIS Neurosciences Inc., October 30, 2024

Important Information and Legal Disclaimers Leede Financial Inc. (Leede) is a member of the Canadian Investment Regulatory Organization (CIRO) and a member of the Canadian Investor Protection Fund (CIPF). This document is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular investing strategy. Data from various sources were used in the preparation of these documents; the information is believed but in no way warranted to be reliable, accurate and appropriate. All information is as of the date of publication and is subject to change without notice. Any opinions or recommendations expressed herein do not necessarily reflect those of Leede. Leede cannot accept any trading instructions via e-mail as the timely receipt of e-mail messages, or their integrity over the Internet, cannot be guaranteed. Dividend yields change as stock prices change, and companies may change or cancel dividend payments in the future. All securities involve varying amounts of risk, and their values will fluctuate, and the fluctuation of foreign currency exchange rates will also impact your investment returns if measured in Canadian Dollars. Past performance does not guarantee future returns, investments may increase or decrease in value, and you may lose money. Leede employees may buy and sell shares of the companies that are recommended for their own accounts and for the accounts of other clients. Disclosure codes are used in accordance with Policy 3600 of CIRO.

Description of Disclosure Codes 1. Leede and its affiliates collectively beneficially own 1% or more of any class of equity securities of the company as of the end of the preceding month or the month prior to the preceding month if the report was issued prior to the 10th. 2. The analyst or any associate of the analyst responsible for the report or public comment hold shares or is short any of the company's securities directly or through derivatives. 3. Leede or a director or officer of Leede or any analyst provided services to the company for remuneration other than normal investment advisory or trade execution services within the preceding 12 months. 4. Leede provided investment banking services for the company during the 12 months preceding the publication of the research report. 5. Leede expects to receive or intends to seek compensation for investment banking services in the next three months. 6. The analyst preparing the report received compensation based upon Leede investment banking revenues for this issuer within the preceding 12 months. 7. The director, officer, employee, or research analyst is an officer, director or employee of the company, or serves in an advisory capacity to the company. 8. Leede acts as a market maker of the company. 9. The analyst has conducted a site visit and has viewed a major facility or operation of the issuer. 10. The company has paid for all, or a material portion, of the travel costs associated with the site visit by the analyst.

Dissemination All final research reports are disseminated to existing and potential institutional clients of Leede Financial Inc. (Leede) in electronic form to intended recipients thorough e-mail and third-party aggregators. Research reports are posted to the Leede website and are accessible to customers who are entitled to the firm’s research. Reproduction of this report in whole or in part without permission is prohibited.

Research Analyst Certification The Research Analyst(s) who prepare this report certify that their respective report accurately reflects his/her personal opinion and that no part of his/her compensation was, is, or will be directly or indirectly related to the specific recommendations or views as to the securities or companies. Leede Financial Inc. (Leede) compensates its research analysts from a variety of sources and research analysts may or may not receive compensation based upon Leede investment banking revenue.

Canadian Disclosures This research has been approved by Leede Financial Inc. (Leede), which accepts sole responsibility for this research and its dissemination in Canada. Leede is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF). Canadian clients wishing to effect transactions in any designated investment discussed should do so through a Leede Registered Representative.

U.S. Disclosures This research report was prepared by Leede Financial Inc. (Leede). Leede is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF). This report does not constitute an offer to sell or the solicitation of an offer to buy any of the securities discussed herein. Leede is not registered as a broker-dealer in the United States and is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. Any resulting transactions should be effected through a U.S. broker-dealer.

( Companies Mentioned: PMN:TSX; PMN:NCM, )

Source: Streetwise Reports 11/05/2024

Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has announced the release of its newly updated Medical Education Suite (MES). This release aligns with the company's active participation in a major symposium focused on AI assessment in medical education. The Symposium, hosted by the University of Minnesota Medical School,  drew thought leaders and representatives from over 50 medical schools and national education organizations across the United States and internationally.

The updated MES has been designed to leverage Treatment's proprietary Global Library of Medicine (GLM) to help reduce the administration overhead and associated time and costs for medical schools in running key exams, such as the Objective Structured Clinical Examination (OSCE). Additionally, this updated version of the MES includes "easy to use" features to further support students in their clinical assessment training and exam preparation. This OSCE exam is seen as a critical evaluation used globally to assess the practical skills of medical students. It is now employed in more than 80 countries, with between 200,000 to 300,000 students participating annually.¹

The MES incorporates various AI-driven features, such as automated case generation for OSCE exams, scripts for simulated patients, and instant scoring with personalized feedback. The Suite also introduces new tools, including AI Patient, which supports students preparing for medical exams, and expanded OSCE case packages, which are expected to grow to a library of 100 cases by the end of Q4 2024. Additionally, the AI Prep Tool offers both non-guided and guided exam-simulated modes, assisting students in honing their clinical reasoning.

Kevin Peterson, MD, MPH, Treatment's Chief Medical Officer, delivered a keynote at the Symposium, joining an impressive lineup that includes presenters from Mayo Clinic and the University of Alberta. The company highlights that this Symposium is a crucial opportunity to demonstrate its MES and showcase its growing influence in the field of medical education.

CEO Dr. Essam Hamza emphasized the significance of this event, stating in the press release, "We are excited to showcase our updated medical education software suite at this landmark Symposium. The opportunity to have a positive impact on the medical training of students and, in turn, introduce them to our range of proprietary AI tools is an important inflection point in the company's commercialization timeline."

AI in Healthcare

On October 10, Microsoft emphasized the importance of multimodal AI models for a comprehensive assessment of patient health. The report highlighted the growing importance of using AI to analyze complex, multimodal health data, such as medical imaging, genomics, and clinical records. The integration of these data sources has enabled more precise diagnostics and treatment planning, illustrating the sector's move toward comprehensive AI applications. The healthcare industry has faced challenges like the need for large-scale, integrated datasets and significant computational resources, but advancements have begun to bridge these gaps. Microsoft noted that these developments would help unlock new insights and improve patient care by accelerating innovation and enhancing clinical decision-making across the sector.

On November 4, Forbes reported that AI-powered healthcare tools were no longer merely experimental but were instead delivering real value across the industry. Examples included enhanced diagnostic accuracy through AI algorithms, like those developed by Google Cloud Healthcare, and improved administrative processes through platforms like Cedar's AI-powered billing system. Forbes noted that these developments were reshaping patient care and reducing administrative burdens, offering measurable benefits.

Also, on November 4, Tech Target highlighted the optimism among healthcare professionals regarding generative AI's potential to alleviate administrative burdens. Over 90% of healthcare workers surveyed expressed confidence in generative AI's ability to simplify tasks like prior authorizations and nurse handoff reports. Aashima Gupta from Google Cloud shared insights on these tools' transformative capabilities, while Tony Farah from Highmark Health cited an 85% reduction in provider administrative costs after automating prior authorizations. Helen Waters from Meditech added, "We believe that gen AI and AI overall is transforming how healthcare professionals access and use information to make powerful decisions confidently," reflecting the positive impact of AI tools on healthcare workflows and decision-making.

Company Catalysts

Treatment.com AI Inc. continues to evolve its medical education platform, incorporating advanced AI technologies that could help revolutionize medical education and training. The company is leveraging its Global Library of Medicine, which offers over 10,000 medical reviews and covers more than 1,000 diseases and associated symptoms. These AI-driven tools aim to enhance clinical decision-making while reducing administrative burdens for healthcare institutions.

The updated MES is projected to impact medical training through its comprehensive and AI-enhanced features, as outlined in Treatment's investor presentation. The presentation details the significant market potential, with the AI healthcare market expected to grow from US$11 billion in 2021 to US$187 billion by 2030, according to Statista. In addition to Treatment's announced new functionality, the company has already begun work on further solutions such as AI Doctor in a Pocket and audio/video analysis tools for clinical scoring and diagnostics. The goal of this expanded portfolio is to position the company to help expedite its aggressive growth plans over the next year.

Analysis of Treatment.com AI

Ownership and Share Structure

According to Sedi.ca, insiders own approximately 8% of Treatment.com AI. Retail investors own the remaining 92%. 

The company has 48.99 million outstanding common shares and has 41.3 million free float traded shares.

As of November 4, the market cap is approximately CA$31.35 million. Over the past 52 weeks, the company traded between CA$0.355 and CA$1.11 per share.

¹Source bodies including: https://www.aamc.org/; https://www.uems.eu/; https://www.nmc.org.in/; Education – GMC (gmc-uk.org)

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Treatment.com AI has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Treatment.com AI.
3. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

* Disclosure for the quote from the Clive Maund article published on [Date]

1. For the quoted article (published on [Date]), the Company has paid Street Smart, an affiliate of Streetwise Reports, between US$1,500 and US$2,500.
2. Author Certification and Compensation: [Clive Maund of clivemaund.com] is being compensated as an independent contractor by Street Smart, an affiliate of Streetwise Reports, for writing the article quoted. Maund received his UK Technical Analysts’ Diploma in 1989. The recommendations and opinions expressed in the article accurately reflect the personal, independent, and objective views of the author regarding any and all of the designated securities discussed. No part of the compensation received by the author was, is, or will be directly or indirectly related to the specific recommendations or views expressed

Clivemaund.com Disclosures

The quoted article represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks cannot be only be construed as a recommendation or solicitation to buy and sell securities.

¹Source bodies including: https://www.aamc.org/; https://www.uems.eu/; https://www.nmc.org.in/; Education – GMC (gmc-uk.org)

( Companies Mentioned: TRUE:CSE; TREIF:OTCMKTS;939:FRA, )

Source: Dr. Joseph Pantginis 11/04/2024

H.C. Wainwright & Co. analysts Dr. Joseph Pantginis, Dr. Lander Egaña Gorroño, Dr. Joshua Korsen, Dr. Matthew Keller, and Dr. Sara Nik, in a research report published on November 4, 2024, maintained their Buy rating on Lexicon Pharmaceuticals Inc. (LXRX:NASDAQ) with a price target of US$6.00. The report follows Lexicon's presentation of preclinical data for LX9851, its ACSL5 inhibitor for obesity, at ObesityWeek 2024.

The analysts highlighted key findings from the presentations, stating, "LX9851 promotes reduction of fat mass without affecting lean body mass" and "LX9851 improves and sustains GLP-1 RA-mediated weight loss, even after semaglutide discontinuation." They added that "Mechanistic studies suggest that LX9851-mediated ACSL5 inhibition activates the ileal brake."

Regarding the drug's potential, they noted, "LX9851 is a first-in-class, oral small molecule ACSL5 inhibitor designed to enhance and maintain weight loss promoted by incretin mimetics (GLP-1 receptor agonists), and offer improved treatment alternatives for obesity and related metabolic disorders."

The report also addressed recent developments with sotagliflozin, detailing the AdCom voting results and potential scenarios for FDA action. The analysts stated, "Although we anticipate favorable feedback from the agency regarding eGFR ≥60 to <90 range, our bet is that a confirmatory trial may be required to validate sota's efficacy in this subpopulation and obtain approval."

H.C. Wainwright & Co.'s valuation methodology is based on a clinical net present value (NPV) model. The analysts explained, "Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's profile. We currently value Lexicon solely on sotagliflozin sales in the U.S. for HF (INPEFA), HCM, and LX9211 for DPNP."

They added, "We believe significant upside potential exists, based on: (1) attaining higher market penetration for HF, and HCM; and (2) adding the earlier stage assets."

In conclusion, H.C. Wainwright & Co.'s maintenance of their Buy rating and US$6 price target reflects confidence in Lexicon's pipeline potential, particularly with LX9851 and sotagliflozin. The share price at the time of the report of US$1.22 represents a potential return of approximately 392% to the analysts' target price, highlighting the significant upside potential if the company's development programs prove successful.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co., Lexicon Pharmaceuticals Inc., November 4, 2024

This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet. H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility.

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Joseph Pantginis, Ph.D., Lander Egaña Gorroño, Ph.D., Joshua Korsen, Ph.D., Matthew Keller, Ph.D. and Sara Nik, Ph.D. , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of Lexicon Pharmaceuticals, Inc. (including, without limitation, any option, right, warrant, future, long or short position). As of September 30, 2024 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Lexicon Pharmaceuticals, Inc..

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report. The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The firm or its affiliates received compensation from Lexicon Pharmaceuticals, Inc. for non-investment banking services in the previous 12 months. The Firm or its affiliates did not receive compensation from Lexicon Pharmaceuticals, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in Lexicon Pharmaceuticals, Inc. as of the date of this research report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

( Companies Mentioned: LXRX:NASDAQ, )

Source: Dr. David Nierengarten 11/07/2024

TScan Therapeutics Inc. (TCRX:NASDAQ) Phase 1 ALLOHA study, evaluating its lead therapeutic candidates TSC-100 and TSC-101 in hematologic malignancies, showed patients continuing to have a positive response after one year, reported Wedbush analyst Dr. David Nierengarten in a Nov. 5 research note. TSC-100 and TSC-101 are T-cell receptor-engineered T-cell therapies (TCR-Ts).

"We see a catalyst-rich next few months ahead with data building in prominence on stock impact," Nierengarten wrote.

87% Return Potential

Wedbush has a US$10 per share target price on the Massachusetts-based biotech, trading at the time of the report at about US$5.36 per share, noted the analyst. The difference between these figures implies an 87% return potential for investors.

TScan Therapeutics remains rated Outperform.

Durability of Response Data

Nierengarten presented the clinical trial's latest results. As of the July 8, 2024 data cutoff date, in Phase 1 of ALLOHA, 16 patients with hematologic tumors had been administered TSC-100 or TSC-101, and 11 patients had been given a placebo. Median follow-ups had occurred at 5.8 months and 5.3 months, respectively.

At the time, none of the patients in the treatment arm had had a relapse. In the control arm, however, three, or 27% of, the 11 patients had, and the median time to relapse was 159 days. The analyst explained that this is typical for patients receiving a hematopoietic stem cell transplant after reduced-intensity conditioning.

One year out from treatment, five patients were evaluable, and all remained relapse free and minimal residual disease negative at the time. These data underscore the durability of response to this TCR-T treatment, Nierengarten commented. Its safety profile was shown to be favorable still, with no patients experiencing dose-limiting toxicities or adverse events associated with allogeneic hematopoietic cell transplantation.

"Enrollment continues in dose expansion cohorts, and results could support a registrational trial as early as 2025, pending regulatory feedback," Nierengarten wrote.

On the Horizon

TScan Therapeutics has several catalysts related to its clinical programs on the horizon, which Nierengarten listed.

On Nov. 8 and 9, the company will present preclinical data in the poster sessions at the annual Society for Immunotherapy of Cancer meeting. One poster will show in vitro combinatorial data for T-Plex, TScan's cellular therapy for treating solid tumors. It is comprised of two to three different TCR-Ts that target different tumor antigens on different human leukocyte antigen (HLA) types.

A second poster will detail the expansion of ImmunoBank, the biotech's diverse bank of therapeutic T-cell receptors (TCRs) that recognize diverse targets and are associated with multiple HLA types. The third will depict development of a target agnostic platform to evaluate how TCR-Ts affect primary human tissues.

On Dec. 9, TScan Therapeutics will present updated one-year data from ALLOHA, at the American Society for Hematology Annual Meeting in December.

By year-end, the biotech will announce initial data from administering singleplex therapy, cell therapy engineered using a single TCR, to patients with solid tumors. This treatment is being given to establish safety before administering multiplex therapy, cell therapy engineered from multiple TCRs.

In 2025, TScan Therapeutics will provide long-term duration of response data for multiplex therapy in solid tumors and will potentially commence a registrational trial for TSC-100 and TSC-101.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Wedbush, TScan Therapeutics Inc., November 5, 2024

Analyst Certification We, David Nierengarten, Martin Fan and Dennis Pak, certify that the views expressed in this report accurately reflect our personal opinions and that we have not and will not, directly or indirectly, receive compensation or other payments in connection with our specific recommendations or views contained in this report.

Company Specific Disclosures This information is subject to change at any time. 1. WS makes a market in the securities of TScan Therapeutics, Inc.. 6. WS is acting as a financial advisor for TScan Therapeutics, Inc..

Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request. Disclosure information regarding historical ratings and price targets is available: Research Disclosures *WS changed its rating system from (Strong Buy/ Buy/ Hold/ Sell) to (Outperform/ Neutral/ Underperform) on July 14, 2009. Applicable disclosure information is also available upon request by contacting the Research Department at (212) 833-1375, by email to leslie.lippai@wedbush.com. You may also submit a written request to the following: Wedbush Securities, Attn: Research Department, 142 W 57th Street, New York, NY 10019.

OTHER DISCLOSURES The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the information contained herein may be obtained upon request. Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see pages 3–7 of this report for analyst certification and important disclosure information. Retail Investors The information provided is for general informational purposes only and should not be considered an individual recommendation or personalized investment advice. The companies/investments mentioned may not be suitable for everyone. Each investor needs to review their own respective situation(s) before making any investment decisions. All expressions of opinion are subject to change without notice due to shifting market(s), economic or political conditions. Investment involves risks including the risk of principal. Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.

( Companies Mentioned: TCRX:NASDAQ, )

WHEN: Wed, November 18Time: 10am PT / 1pm ET  Join Now!SPONSORED BY: Nortel and AT&TJoin leading mobility experts to hear why only the mobile enterprise will survive! Join Now!Why the mobile ...

On-Demand Webinar > Watch Now!>>SPONSORED BY: TripwireResearch shows that over a third of organizations are not prepared for breaches while the average cost per breach in 2009 was $6.7 millio...

On-Demand Webinar >  Watch Now!>>SPONSORED BY: VeriSignWatch this FREE on-demand webinar to hear from Michael E. Dortch, Focus Research Director, and Security Analyst, Larry Seltzer, as ...

Aero Energy Ltd. (AERO:TSXV; AAUGF:OTC; UU3:FRA) has announced significant advancements at its Murmac and Sun Dog uranium projects in Northern Saskatchewan. Read how this and a CA$2.5-million non-brokered private placement aim the company towards further exploration.

Operationally, the company's renewable energy generation was up 397% year over year. Discover the many potential catalysts for the stock.

Poet Amanda Gorman speaks at the inauguration of U.S. President Biden on the West Front of the U.S. Capitol on Wednesday.; Credit: Alex Wong/Getty Images

When Amanda Gorman, a 22-year-old poet from Los Angeles, took to the stage on Wednesday, it was immediately clear why the new president had chosen her as his inaugural poet.

Gorman echoed, in dynamic and propulsive verse, the same themes that Biden has returned to again and again and that he wove throughout his inaugural address: unity, healing, grief and hope, the painful history of American experience and the redemptive power of American ideals.

Where Biden said, "We must end this uncivil war," Gorman declared, "We lay down our arms so we can reach out our arms to one another."

And where Biden called for an American story of "love and healing" and "greatness and goodness," Gorman saw strength in pain: "Even as we grieved, we grew," she said.

Gorman opened by acknowledging the reasons why hope can be challenging. "Where can we find light in this never-ending shade?" she asked.

But she continued: "And yet, the dawn is ours before we knew it. Somehow we do it. Somehow we weathered and witnessed a nation that isn't broken but simply unfinished."

She acknowledged the power of her own presence on the stage in "a country and a time where a skinny black girl descended from slaves and raised by a single mother can dream of becoming president, only to find herself reciting for one."

Like Obama inaugural poet Richard Blanco, who invoked the grand sweep of American geography in a call for unity in "One Today," Gorman dedicated a portion to "every corner called our country" from the South to the Midwest. She ended with an invitation to "step out of the shade."

"The new dawn blooms as we free it," she said. "For there is always light, if only we are brave enough to see it – if only we are brave enough to be it."

Gorman was following in the footsteps of poets like Blanco, Robert Frost and Maya Angelou as she composed the poem "The Hill We Climb" for the inauguration.

She also took her cues from orators like Frederick Douglass, Abraham Lincoln and Martin Luther King, Jr. — people who knew a thing or two about calling for hope and unity in times of despair and division.

Gorman told NPR she dug into the works of those speakers (and Winston Churchill, too) to study up on ways "rhetoric has been used for good." Over the past few weeks, she composed a poem that acknowledges the previous president's incitement of violence, but turns toward hope.

"The Hill We Climb" reads, in part:

We've seen a force that would shatter our nation rather than share it,

Would destroy our country if it meant delaying democracy.

And this effort very nearly succeeded.

But while democracy can be periodically delayed,

It can never be permanently defeated.

In this truth, in this faith, we trust.

For while we have our eyes on the future,

history has its eyes on us.

Gorman, like Biden, had a speech impediment as a child. (Biden had a stutter; Gorman had difficulty pronouncing certain sounds.) She told NPR's Steve Inskeep that her speech impediment was one reason she was drawn to poetry at a young age.

"Having an arena in which I could express my thoughts freely was just so liberating that I fell head over heels, you know, when I was barely a toddler," she said.

For Gorman, a former National Youth Poet Laureate, her struggle to speak provided a connection not only to the incoming president, but also to previous inaugural poets, too.

"Maya Angelou was mute growing up as a child and she grew up to deliver the inaugural poem for President Bill Clinton," she says. "So I think there is a real history of orators who have had to struggle with a type of imposed voicelessness, you know, having that stage in the inauguration."

Barack Obama, Bill Clinton and John F. Kennedy were the only presidents in the past who chose to have poems read at their inaugurations. You can read all the previous poems here.

This content is from Southern California Public Radio. View the original story at SCPR.org.

; Credit: /Katherine Du

Over the years, NPR's poetry community has turned both painful and joyful experiences into magnificent work.

As the world still endures the coronavirus pandemic, the U.S. also grieves over increased violence against Asian Americans and a mass shooting in Georgia that left six women of Asian descent dead.

"Let's be clear: Anti-Asian violence and discrimination are not new. But, this racism seems to be heightened," says Kwame Alexander, NPR's resident poet. "And the onus is not on Asian Americans to figure this out. Frankly, it's on white people, it's on the rest of us — individually, systemically, to talk about it, to pay attention to, advocate against it."

"Between Autumn Equinox and Winter Solstice, Today," by Emily Jungmin Yoon, is a list poem that reflects the coldness of the world and how it wears on us. Yoon is a South Korean-born poet pursuing her Ph.D. in Korean literature at the University of Chicago.

Alexander and Morning Edition's Rachel Martin ask listeners: How do you cope with recent anti-Asian violence and discrimination? Tell us in a list poem.

Your poem doesn't have to rhyme. It just needs to have an ordered list with details that show your state of mind — and must begin with the word "today."

Share your poem through the form below. Then Alexander will take lines from some of your pieces and create a community crowdsourced poem. Alexander and Martin will read it on air, and NPR will publish it online, where contributors will be credited.

Submissions are due by noon ET on Monday, April 5.

Here are the terms of the callout:

By providing your Submission to us, you agree that you have read, understand and accept the following terms in relation to the content and information (your "Submission") you are providing to National Public Radio ("NPR," "us" or "our"):

You are submitting content pursuant to a callout by Morning Edition related to a segment with Kwame Alexander wherein he creates unique poetry based on listener submissions. You understand that you are submitting content for the purpose of having Kwame use that content to create a new poem or poems ("Poem") with the material you submit. You must be over the age of 18 to submit material.

You will retain copyright in your Submission, but agree that NPR and/or Kwame Alexander may edit, modify, use, excerpt, publish, adapt or otherwise make derivative works from your Submission and use your Submission or derivative works in whole or in part in any media or format and/or use the Submission or Poem for journalistic and/or promotional purposes generally, and may allow others to do so. You understand that the Poem created by Kwame Alexander will be a new creative work and may be distributed through NPR's programs (or other media), and the Poem and programs can be separately subject to copyright protection. Your Submission does not plagiarize or otherwise infringe any third-party copyright, moral rights or any other intellectual property rights or similar rights. You have not copied any part of your Submission from another source. If your Submission is selected for inclusion in the Poem, you will be acknowledged in a list of contributors on NPR's website or otherwise receive appropriate credit, but failure to do so shall not be deemed a breach of your rights.

Your submission will be governed by our general Terms of Use and Privacy Policy. As the Privacy Policy says, we want you to be aware that there may be circumstances in which the exemptions provided under law for journalistic activities or freedom of expression may override privacy rights you might otherwise have.

This content is from Southern California Public Radio. View the original story at SCPR.org.

GoldMining Inc. (GOLD:TSX; GLDG:NYSE.American) released results from its ongoing 2024 auger drilling program at the Sao Jorge Project in the Tapajos gold district, Para State, Brazil. Read more about high-grade gold intercepts and new exploration targets at So Jorge as GoldMining extends its search in Tapajs.

Western Exploration Inc. (WEX:TSX.V; WEXPF:OTC) announces more high-grade results from its drilling program at its fully owned Aura gold-silver project in Nevada. Find out why one analyst thinks the company is aligned for M&A attention.

Cars make their way toward downtown Los Angeles on April 22. California could regain the right to set its own vehicle emissions standards after the Environmental Protection Agency announced it was moving to curb a Trump-era policy that sought to erode the state's previously-held power.; Credit: Mario Tama/Getty Images

The Environmental Protection Agency (EPA) said on Monday it is preparing to restore California's right to set its own vehicle emissions standards, in a widely anticipated reversal of Trump-era policies.

The decision, which will take several months to be finalized, reaffirms the Golden State's powerful position as an environmental regulator after the Trump administration had in 2019 sought to remove California's powers to set its own emissions standards.

It also sets the stage for negotiations over how strict federal vehicle standards will be under President Biden.

"I am a firm believer in California's long-standing statutory authority to lead," EPA administration Michael Regan said in a statement.

"The 2019 decision to revoke the state's waiver to enforce its greenhouse gas pollution standards for cars and trucks was legally dubious and an attack on the public's health and wellbeing," he added.

The EPA will be accepting public comment until July 6 as part of the process of reversing the Trump-era rule.

The populous, car-loving state has been waging a battle against smog for decades.

And in recognition of that history, the EPA has long granted a waiver giving the state the authority to set its own standards for vehicle emissions, as long as they're more stringent than the national regulations.

That's an unusual exemption — other states can't set their own policies, although they can choose to adopt California's standards as their own.

Between California and the states that follow suit, about a third of the U.S. new car market is covered by the Golden State's policies, giving California regulators a remarkable amount of sway over the auto industry.

However, when the Trump administration weakened federal clean car standards, it also sought to revoke the waiver allowing California to set a higher bar.

That triggered a legal battle and divided the auto industry, with some carmakers choosing to side with California and voluntarily accept somewhat stricter vehicle emissions standards while the rest backed the Trump administration.

After Biden won the White House, every major automaker eventually dropped their support for the now-doomed Trump position.

The EPA has now started the process of reversing Trump's decision. The Department of Transportation last week also proposed to "wipe clean the regulatory slate," indicating that the National Highway Traffic Safety Administration would no longer seek to block state emissions standards, as it had under Trump.

It's still not clear what federal regulations on vehicle emissions and fuel economy will be under the Biden administration. Some environmental groups and progressive lawmakers are pushing for the reinstatement of the Obama-era standards, with more ambitious targets to follow.

The auto industry, meanwhile, is calling for standards midway between the Obama-era and Trump-era policies.

The EPA says it will propose new fuel economy rules in July.

This content is from Southern California Public Radio. View the original story at SCPR.org.

• Provide the utmost Child Support Services by always providing excellent customer service to internal and external customers.

• Advocating for children to receive the financial stability that they deserve and providing the best customer service to all that we serve.

• Building relationships with all parties involved as well as stakeholders to obtain an order of support or to enforce an order support, so that children can receive the financial support they need and deserve.

• Striving for excellence in meeting all mandated standards in a fast – paced rewarding environment that ultimately seeks to provide financial stability for children, parents and caretakers.

Traffic on Interstate 95 was diverted for hours after a group of armed men fled from police near Wakefield, Mass. on Saturday. Massachusetts state police say 11 suspects have been taken into custody.; Credit: Michael Dwyer/AP

Eleven people were taken into custody Saturday after an hours-long standoff with police early Saturday outside Boston.

While police engaged in negotiation, members of the group engaged the public on social media, saying their group was called "Rise of the Moors."

The heavily armed men were said to be driving from Rhode Island to Maine for "training."

The incident started around 1:30 a.m., when state police noticed two cars stopped at the side of I-95 near Wakefield, Mass., apparently out of fuel. As troopers stopped to assist, they noticed that some individuals near the cars had "military-style" gear, and were carrying long guns and pistols, Massachusetts State Police Col. Christopher Mason told reporters.

"You can imagine 11 armed individuals standing with long guns slung on an interstate highway at 2 in the morning certainly raises concerns and is not consistent with the firearms laws that we have in Massachusetts," Mason said.

Police requested backup, and thus began a standoff that lasted several hours. The men refused to lower their weapons, saying that they "don't recognize our laws," police said. Some of the armed men fled into a nearby wooded area, police said, and a portion of I-95 was closed for several hours.

The standoff was broadcast on social media

Around 4 a.m., a man whom the Boston Globe identified as Jamhal Talib Abdullah Bey said he was broadcasting live from I-95 and said that he told police they had nothing to fear.

"I reassured them that we are not sovereign citizens," a man who appeared to be Bey said in a live-streamed video. "I reassured them that we are not Black identity extremists. I reassured them that we are not anti-police. I reassured them that we are not anti-government. I reassured them that these men here will not be pointing guns at them. I reassured them that we are trying to come to a peaceful resolution."

"We're going to our private land to train, which is our Second Amendment right," he said, showing a vehicle he said contained camping equipment.

As police tactical teams brought in armored vehicles to surround the area, and negotiators interacted with the men, they ultimately surrendered. Middlesex County District Attorney Marian Ryan told reporters the suspects were expected to appear in court on Tuesday morning.

State police "don't have any knowledge about this particular specific group" but as state police "it is not unusual for us to encounter people that have sovereign citizen ideologies — I'm not saying that this group does — but we have had those encounters before in the past," Mason said at a Saturday morning press briefing.

"We train to those encounters," Mason continued. "We very much understand the philosophy that underlies that mindset. And we train our officers, actually, at the academy, on these interactions and how to de-escalate those situations, and how to engage with people that have that philosophy and mindset and resolve those situations in a peaceful manner."

The group calls itself "Rise of the Moors"

The same man appearing to be Bey said in a later video: "They keep portraying us as being anti-government, but we're not anti-government at all."

The group's website lists Bey as a leader of the "Rhode Island State Republic and Providence Plantations." According to the site, Bey served in the military for four years, some or all of that time in the Marines, after which he began studying "Moorish Science."

That website, "Rise of the Moors," explains that Moors are not "sovereign citizens" because "sovereignty does not stand alone," but can rather be considered synonymous with "nationality."

"The record show that the Moors are the organic or original sovereigns of this land — America," the FAQ says. "When we declare our nationality as Moorish Americans we are taking back the position as the aboriginal people of the land, to which the sovereign power is vested in."

Bey's group may be associated with the Moorish sovereign citizen movement, which the Southern Poverty Law Center characterizes as an offshoot of the antigovernment sovereign citizens movement. Moorish sovereigns "have come into conflict with federal and state authorities over their refusal to obey laws and government regulations," SPLC writes.

"The Moorish Sovereign movement is a rapidly growing group of people who believe that they belong to a sovereign nation that has a treaty with the US but otherwise operates outside of the federal and state laws," JJ MacNab, a fellow at George Washington University's Program on Extremism, explained on Twitter.

"They rely on an alternative history that borrows from Moorish Science Temple, Black Hebrew Israelism, Nation of Islam, UFO theories, phony Native American tribes, and the pseudo-legal arguments crafted by white supremacist 'patriot' groups in the 1970s," MacNab said.

This content is from Southern California Public Radio. View the original story at SCPR.org.